GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

Investing.com -- GSK (NYSE: GSK) (LON: GSK) said on Monday that the U.S. Food and Drug Administration has accepted its ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain’s GSK and Germany’s CureVac US$740 ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on ...

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

La biotecnológica CureVac, que no cotiza en bolsa, se convertirá en la segunda empresa en iniciar ensayos con humanos de una vacuna experimental contra el coronavirus en Alemania, informó el ...